FDA approves Opdivo to treat advanced form of kidney cancer

FDA approves Opdivo to treat advanced form of kidney cancer

Управление США по санитарному надзору за качеством пищевых продуктов и медикаментов (Food and Drug Administration - FDA) сегодня одобрило препарат Опдиво (ниволумаб) для лечения больных с распространенным (метастатическим) почечно-клеточным раком (форма рака почки), которые получили определенный вар...

Full description

Bibliographic Details
Main Author:	- -
Format:	Article
Language:	Russian
Published:	IP Habib O.N. 2015-12-01
Series:	Современная онкология
Online Access:	https://modernonco.orscience.ru/1815-1434/article/view/27004

Similar Items

Repurposing FDA approved drugs as radiosensitizers for treating hypoxic prostate cancer
by: Becky A. S. Bibby, et al.
Published: (2021-07-01)

Natural Products, Alone or in Combination with FDA-Approved Drugs, to Treat COVID-19 and Lung Cancer
by: Liyan Yang, et al.
Published: (2021-06-01)

Why did the FDA approve these advertisements?
by: David Oaks
Published: (2006-02-01)

Announcement Effect of Drug Approvals by FDA
by: Ting, Hsiu Wen, et al.
Published: (2008)

FDA approved ready to use phenylephrine
by: Pradeep Kumar Bhatia, et al.
Published: (2021-01-01)

The effect and molecular action of curcumin in FDA-approved clinical drug-treated human bladder cancer cells
by: Ya-Wen Fan, et al.
Published: (2014)

Repurposing FDA-approved drugs as therapeutics to treat Rift Valley fever virus infection
by: Ashwini eBenedict, et al.
Published: (2015-07-01)

The current landscape of the FDA approved companion diagnostics
by: Jan Trøst Jørgensen
Published: (2021-06-01)

Anti-Cancer Drugs Targeting Protein Kinases Approved by FDA in 2020
by: Jonas Cicenas, et al.
Published: (2021-02-01)

Clinical and economic analysis of effectiveness of Nivolumab (Opdivo®) use as second-line monotherapy in adult patients with advanced renal cell carcinoma after previous systemic therapy
by: M. Yu. Frolov, et al.
Published: (2017-04-01)

European Medicines Agency extension of indication to include the combination immunotherapy cancer drug treatment with nivolumab (Opdivo) and ipilimumab (Yervoy) for adults with intermediate/poor-risk advanced renal cell carcinoma
by: Jorge Camarero, et al.
Published: (2020-12-01)

FDA efficiency for approval process of COVID-19 therapeutics
by: Christine Cassidy, et al.
Published: (2020-12-01)

The Biosimilar Landscape: An Overview of Regulatory Approvals by the EMA and FDA
by: Ioana Gherghescu, et al.
Published: (2021-12-01)

A Comprehensive Map of FDA-Approved Pharmaceutical Products
by: Hao Zhong, et al.
Published: (2018-12-01)

THPdb: Database of FDA-approved peptide and protein therapeutics.
by: Salman Sadullah Usmani, et al.
Published: (2017-01-01)

An evaluation and comparison of current FDA-approved treatments for obesity
by: Bapatla, Neha
Published: (2018)

Quantitative analysis on the characteristics of targets with FDA approved drugs
by: Meena K. Sakharkar, Peng Li, Zhaowei Zhong, Kishore R. Sakharkar
Published: (2008-01-01)

Editorial: FDA-Approved Drug Repositioning for P-Glycoprotein Overexpressing Resistant Cancer
by: Sungpil Yoon, et al.
Published: (2021-03-01)

FDA approves ixazomib in combination with lenalidomide and dexamethasone for multiple myeloma
by: - -
Published: (2015-12-01)

Are FDA-Approved Sunscreen Components Effective in Preventing Solar UV-Induced Skin Cancer?
by: Ann M. Bode, et al.
Published: (2020-07-01)

FDA and EMA Approvals of New Breast Cancer Drugs—A Comparative Regulatory Analysis
by: Chandra P. Leo, et al.
Published: (2020-02-01)

FDA Approval Summary: Abemaciclib With Endocrine Therapy for High-Risk Early Breast Cancer
by: Amiri-Kordestani, L., et al.
Published: (2022)

Concerning FDA approval of trilaciclib (Cosela) in extensive-stage small-cell lung cancer
by: Kerrington Powell, et al.
Published: (2021-11-01)

Combinatorial effects of six FDA approved drugs on influenza virus
by: En-Kai Chang, et al.
Published: (2018)

FDA Approvals and Consensus Guidelines for Botulinum Toxins in the Treatment of Dystonia
by: Lauren L. Spiegel, et al.
Published: (2020-05-01)

Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease
by: Michael M. Boyiadzis, et al.
Published: (2018-05-01)

FDA-approved immunosuppressants targeting staphylococcal superantigens: mechanisms and insights
by: Krakauer T
Published: (2017-05-01)

Timelines of translational science: From technology initiation to FDA approval.
by: Laura M McNamee, et al.
Published: (2017-01-01)

Current FDA-Approved Therapies for High-Grade Malignant Gliomas
by: Jacob P. Fisher, et al.
Published: (2021-03-01)

TMS-Induced Seizure during FDA-Approved Bilateral DMPFC Protocol for Treating OCD: A Case Report
by: Georgios Mikellides, et al.
Published: (2021-09-01)

Authors’ commentary on the article Clinical and economic analysis of effectiveness of Nivolumab (Opdivo®) use as second-line monotherapy in adult patients with advanced renal cell carcinoma after previous systemic therapy
by: M. Y. Frolov
Published: (2017-06-01)

Molecular Determinants for Binding of the FDA-Approved Drugs in Proteins – A Data Mining and Advanced Quantum Chemical Study
by: Alqahtani, Saad Mohammed S
Published: (2017)

Clinical Perspective of FDA Approved Drugs With P-Glycoprotein Inhibition Activities for Potential Cancer Therapeutics
by: Jiun-I Lai, et al.
Published: (2020-11-01)

Lurbinectedin: an FDA-approved inducer of immunogenic cell death for the treatment of small-cell lung cancer
by: Oliver Kepp, et al.
Published: (2020-01-01)

FDA-Approved and Emerging Next Generation Predictive Biomarkers for Immune Checkpoint Inhibitors in Cancer Patients
by: Ye Wang, et al.
Published: (2021-06-01)

Cutaneous Adverse Events in Newly Approved FDA Non-cancer Drugs: A Systematic Review
by: Paul C. Macklis, et al.
Published: (2020-06-01)

Pharmacogenomic Biomarkers in US FDA-Approved Drug Labels (2000–2020)
by: Jeeyun A. Kim, et al.
Published: (2021-03-01)

Activity Profile of an FDA-Approved Compound Library against Schistosoma mansoni.
by: Gordana Panic, et al.
Published: (2015-01-01)

Post-translational modifications of FDA-approved plasma biomarkers in glioblastoma samples.
by: Natalia A Petushkova, et al.
Published: (2017-01-01)

Inhibition of Urease by Disulfiram, an FDA-Approved Thiol Reagent Used in Humans
by: Ángel Gabriel Díaz-Sánchez, et al.
Published: (2016-11-01)